Resection of Perspiratory Glands — Cost, Top Hospitals & Success Rates | MyMedicPlus

Resection of perspiratory (sweat) glands — also called axillary sweat gland excision or suction curettage — is a surgical procedure designed to permanently reduce or eliminate excessive underarm sweating (primary axillary hyperhidrosis). Unlike temporary measures such as botulinum toxin injections or prescription antiperspirants, surgical removal of the eccrine and apocrine glands in the axillae provides long-lasting relief for patients who do not respond to conservative management.

Primary hyperhidrosis affects approximately 4.8% of the global population, with the axillary form being among the most socially disabling. The eccrine sweat glands responsible for thermoregulatory sweating are concentrated in the deep dermis and subdermal fat of the axilla. Surgical techniques aim to destroy or remove these glands while preserving surrounding structures.

Surgical Techniques

• Subcutaneous suction curettage (modified liposuction): A small cannula is inserted through a hidden skin fold; negative pressure and mechanical curettage disrupt and aspirate the sweat gland layer. Most common technique due to minimal scarring and shorter recovery.
• Open excision (en bloc resection): An elliptical incision removes the hair-bearing skin and glandular tissue directly. Provides the highest gland elimination rate but leaves a linear scar and may restrict shoulder movement temporarily.
• Laser-assisted gland ablation (MiraDry® / microwave thermolysis): Energy-based destruction of glands through intact skin. Minimally invasive but may require 2 sessions; considered semi-surgical.
• Endoscopic thoracic sympathectomy (ETS): Severs sympathetic nerve fibers controlling axillary sweat. Reserved for refractory cases due to risk of compensatory sweating.

Suction curettage combined with superficial tumescent liposuction is the current preferred technique at most specialist centres, balancing efficacy with a favourable safety profile.

Sweat gland resection is indicated for conditions where excessive perspiration significantly impairs quality of life and fails conservative treatment:

• Primary axillary hyperhidrosis: Bilateral excessive sweating of the underarms without an identifiable secondary cause. Diagnosed when sweating is present for ≥6 months, bilateral and symmetrical, impairs daily activities, occurs at least once per week, and onset is before age 25.
• Axillary osmidrosis (bromhidrosis): Persistently foul axillary odour caused by bacterial decomposition of apocrine gland secretions. Resection eliminates the apocrine glands, resolving the odour at source.
• Hyperhidrosis refractory to first- and second-line therapies: Patients who have failed aluminium chloride antiperspirants, iontophoresis, botulinum toxin injections, and oral anticholinergic agents.

Palmar, plantar, and facial hyperhidrosis are typically managed with alternative approaches (ETS, botulinum toxin), as gland resection is anatomically impractical at these sites.

Ideal candidates for sweat gland resection meet the following criteria:

• Confirmed diagnosis of primary axillary hyperhidrosis or axillary osmidrosis
• Hyperhidrosis Disease Severity Scale (HDSS) score of 3 or 4 (sweating is barely or not tolerable, frequently interferes with daily activities)
• Failure of at least two conservative treatments (topical antiperspirants, botulinum toxin, or iontophoresis)
• Age ≥18 years; body weight within a reasonable range for the technique selected
• No active axillary skin infection or lymphadenopathy
• Non-smoker or willing to abstain perioperatively
• Realistic expectations regarding residual mild sweating and possible scar

Contraindications include pregnancy or breastfeeding, bleeding diathesis, uncontrolled diabetes, known axillary lymph node pathology, and secondary hyperhidrosis (e.g., thyroid disease, medication-induced) that has not been treated first.

Preoperative starch-iodine (Minor's) test is performed to map the active sweating area, guiding precise surgical planning and maximising gland elimination.

Management of Resection of Perspiratory Glands is individualised based on disease severity, patient age, comorbidities, and patient values. The surgical and endoscopic team develops a personalised plan incorporating the following evidence-based treatment modalities:

• Conservative and lifestyle-based management: For many presentations, targeted lifestyle modification — including nutritional optimisation, graded physical activity, weight management, alcohol and smoking cessation — forms the foundation of care. Regular specialist monitoring and patient self-management education enable early detection of deterioration and empower patients to actively participate in their treatment.
• Pharmacological therapy: Evidence-based drug therapy tailored to disease mechanism and individual patient profile forms the pharmacological backbone. First-line agents are selected per current international guidelines, with treatment escalated to second-line or combination therapy for inadequate responders. Regular monitoring ensures therapeutic efficacy and detects adverse effects early.
• Procedural and interventional approaches: Where pharmacological management is insufficient or specific structural or functional abnormalities are identified, minimally invasive or interventional procedures are considered. These are performed by experienced surgical and endoscopic specialists at accredited facilities with appropriate pre-procedure preparation and post-procedure monitoring protocols.
• Surgical treatment: Surgery is indicated for patients with advanced disease, complications, or conditions unresponsive to medical management. Modern surgical approaches include laparoscopic, robotic-assisted, and image-guided techniques that minimise operative morbidity and accelerate recovery. Surgical decisions are made following multidisciplinary discussion and informed consent.
• Multidisciplinary team (MDT) care: Complex presentations are managed through an MDT integrating expertise from relevant specialties — surgical and endoscopic medicine, radiology, physiotherapy, nutrition, psychology, and palliative care as appropriate. MDT-driven care demonstrably improves outcomes for complex conditions. Patient and family involvement in MDT planning ensures alignment with individual values.
• Emerging and clinical trial options: Access to investigational treatments through clinical trials at specialist centres offers patients with refractory or high-risk presentations the opportunity to access next-generation therapies under systematic monitoring. Trial eligibility is assessed as part of the MDT plan.

• Symptom relief and quality-of-life improvement: Effective Resection of Perspiratory Glands significantly reduces disease burden — alleviating pain, fatigue, functional limitations, and other symptoms impairing daily activities and wellbeing. Validated quality-of-life instruments consistently demonstrate clinically meaningful improvements following successful treatment. Patients report greater physical functioning, emotional wellbeing, and social engagement.
• Prevention of progression and complications: Early, sustained treatment prevents progression from mild to severe disease and reduces the risk of serious complications including organ damage, functional decline, and emergency hospitalisation. Long-term clinical trial data support disease-modifying benefits of appropriately managed Resection of Perspiratory Glands.
• Evidence-based, guideline-directed care: Treatment protocols follow internationally recognised clinical guidelines updated with current best evidence, reducing care variation and ensuring patients receive treatments with the strongest evidence base for their specific condition and severity.
• Access to specialist expertise: Management by a specialist general surgery team provides access to advanced diagnostic tools, treatment modalities, and experienced clinicians. Multidisciplinary team decision-making integrates multiple specialist perspectives to develop comprehensive care plans superior to single-specialty management for complex presentations.
• International treatment access: Accredited specialist hospitals in India, Thailand, and Turkey deliver equivalent expertise to Western centres at 60–80% lower cost. MyMedicPlus connects patients with verified, accredited specialist facilities globally.

As with all surgical procedures, resection of perspiratory glands carries defined risks that should be discussed with the treating surgeon:

Common (up to 20%)

• Temporary bruising, swelling, and tenderness in the axilla (resolves within 2–3 weeks)
• Seroma formation (fluid accumulation under skin); treated by aspiration
• Restricted shoulder movement for 1–2 weeks; resolves with physiotherapy exercises

Uncommon (1–5%)

• Superficial wound dehiscence or delayed healing, particularly in open excision
• Skin necrosis of the axillary skin flap if blood supply is compromised
• Hypertrophic or keloid scar (higher risk in darker skin phototypes)
• Residual or recurrent sweating in ungrafted areas; up to 30% note partial recurrence at 2 years with suction curettage alone

Rare (<1%)

• Injury to intercostobrachial nerve (numbness of medial upper arm)
• Axillary infection requiring antibiotics or drainage
• Compensatory hyperhidrosis at other body sites (more common with ETS)

Patients should seek immediate review if they develop fever, rapidly expanding swelling, purulent discharge, or limb weakness following surgery.

Immediate Post-Operative Period (Days 1–7)

Compression bandaging is maintained for 5–7 days to minimise seroma formation and promote skin adherence. Patients are advised to keep the axilla dry, avoid vigorous arm movements, and refrain from deodorant application for the first week. Oral analgesia (paracetamol ± NSAID) adequately controls post-operative discomfort in most cases.

Short-Term Recovery (Weeks 1–4)

Sutures are removed at 10–14 days. Pendulum arm exercises are encouraged from day 5 to maintain shoulder range of motion. Most patients return to desk work within 5–7 days and resume gym activities by week 3–4. A follow-up appointment at 4 weeks assesses wound healing and treatment response using the starch-iodine test.

Long-Term Follow-Up (3–12 Months)

A formal outcomes assessment using the HDSS and Minor's test is conducted at 3 and 12 months. If residual sweating remains above the patient's threshold, a second session of suction curettage or adjunct botulinum toxin may be offered. Scar management (silicone gel, massage) is initiated from week 4 onwards in patients with a tendency to hypertrophic scarring.

The cost of sweat gland resection varies considerably based on technique, geographic location, and facility type:

• Technique: Suction curettage is generally less expensive than open excision due to shorter operative time and anaesthesia requirements. Microwave thermolysis (MiraDry) is priced per session and often comparable to suction curettage for two sessions.
• Anaesthesia: Local tumescent anaesthesia reduces costs compared to general anaesthesia used in open excision.
• Geographic variation: Procedures in India, Thailand, or Turkey can cost 40–70% less than equivalent procedures in the US, UK, or Australia, with equivalent outcomes at accredited centres.
• Facility fees: Day-case surgical centre versus inpatient hospital room carries different overheads.
• Adjunct botulinum toxin: If required in the post-operative period to treat residual areas, this carries an additional cost every 4–6 months.
• Insurance: Some private insurers cover surgical management of hyperhidrosis when conservative measures have been documented to have failed. Cosmetic indications (osmidrosis alone) are rarely covered.

Request itemised quotes from accredited centres and confirm what is included (surgeon fee, anaesthesia, facility, compression garments, and follow-up consultations).

Several non-surgical and minimally invasive options should be considered before proceeding to gland resection:

• Aluminium chloride antiperspirants (20–25%): First-line treatment; applied nightly. Effective in mild-to-moderate hyperhidrosis but requires continuous use and may cause skin irritation.
• Botulinum toxin A (Botox) injections: Intradermal injections block acetylcholine at eccrine nerve terminals. Achieves 80–90% sweat reduction for 4–6 months. Repeated treatment required; most cost-effective for mild-moderate cases if insurance-covered.
• Iontophoresis: Low-intensity electrical current passed through water temporarily blocks sweat ducts. Used predominantly for palmar and plantar hyperhidrosis; less practical for axillae but applicable.
• Oral anticholinergics (glycopyrronium, oxybutynin): Reduce systemic cholinergic stimulation of sweat glands. Limited by side effects (dry mouth, urinary retention, blurred vision).
• Microwave thermolysis (MiraDry): Non-incisional energy-based destruction. A step between pharmacological and surgical management.
• Endoscopic thoracic sympathectomy (ETS): Definitive surgical option for refractory palmar or axillary hyperhidrosis; carries risk of compensatory sweating in up to 70% of patients and is generally reserved as a last resort.